Table 3.

Effect of ruboxistaurin on laboratory parameters

Parameter	Treatment	Baseline	6 weeks	Within group p-value	Between group p-value
8,12-iso-iPF2α-VI (ng/mg creatinine)	Placebo	5.0 (3.2–6.9)a	4.9 (3.4–5.9)	0.96	0.91
	RBX 32 mg/day	4.0 (2.6–5.2)	4.1 (2.4–5.6)	0.65
Urinary albumin excretion rate (μg/mg creatinine)	Placebo	79 (36–168)	81 (32–344)	0.74	0.85
	RBX 32 mg/day	117 (48–285)	91 (62–498)	0.50
Total cholesterol (mmol/L)	Placebo	4.61 (4.0–5.1)	4.34 (3.9–4.6)	0.15	0.16
	RBX 32 mg/day	4.87 (3.9–5.4)	4.79 (3.8–5.4)	0.45
HDL cholesterol (mmol/L)	Placebo	1.17 (0.9–1.3)	1.18 (0.9–1.3)	0.57	0.77
	RBX 32 mg/day	1.21 (1.0–1.5)	1.22 (1.0–1.5)	0.16
LDL cholesterol (mmol/L)	Placebo	2.69 (2.1–3.1)	2.37 (2.0–2.8)	0.001	0.01
	RBX 32 mg/day	2.74 (2.2–3.4)	2.81 (2.3–3.5)	0.92
Triglycerides (mmol/L)	Placebo	1.53 (1.0–2.1)	1.66 (1.1–2.2)	0.43	0.51
	RBX 32 mg/day	1.60 (1.1–2.1)	1.55 (1.0–2.1)	0.94

^aMedian (interquartile range)